Cumberland Pharmaceuticals
CPIX
30 hedge funds and large institutions have $10.6M invested in Cumberland Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 4 closing their positions.
1.84% less ownership
Funds ownership: 24.61% → 22.77% (-1.8%)
3% less funds holding
Funds holding: 31 → 30 (-1)
11% less call options, than puts
Call options by funds: $101K | Put options by funds: $113K
14% less capital invested
Capital invested by funds: $12.3M → $10.6M (-$1.7M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$93K |
| 2 |
Renaissance Technologies
New York
|
+$68.1K |
| 3 |
Two Sigma Investments
New York
|
+$17.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.6K |
| 5 |
BlackRock
New York
|
+$3.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$589K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$133K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$110K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$47.2K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$41.7K |
CPIX Hedge Fund Activity: Q3 2025 in Review
30 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2025, worth a combined $10.6M — down 14% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CPIX and 3 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 6 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $93K. The largest seller was Millennium Management, cutting an estimated $589K.
- 30 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2025, down from 31 in Q2 2025.
- Funds reported $10.6M of Cumberland Pharmaceuticals stock for Q3 2025, down 14% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q3 2025 was Dimensional Fund Advisors, an estimated $93K added.
- The largest Cumberland Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $589K sold.
Based on aggregated 13F filings for Q3 2025.